EQL Pharma Résultats passés
Passé contrôle des critères 2/6
EQL Pharma a connu une croissance annuelle moyenne de ses bénéfices de 12.3%, tandis que le secteur Healthcare a vu ses bénéfices augmenter de en hausse à 6.8% par an. Les revenus ont augmenté de en hausse à un taux moyen de 11.6% par an. Le rendement des capitaux propres de EQL Pharma est 4.7% et ses marges nettes sont de 2.9%.
Informations clés
12.31%
Taux de croissance des bénéfices
12.19%
Taux de croissance du BPA
| Healthcare Croissance de l'industrie | 8.09% |
| Taux de croissance des recettes | 11.61% |
| Rendement des fonds propres | 4.69% |
| Marge nette | 2.90% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Article d’analyse • Nov 15
EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from EQL Pharma AB (publ) ( STO:EQL ) was disappointing to investors, with a sluggish...Article d’analyse • May 16
EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
EQL Pharma AB (publ) ( STO:EQL ) just reported some strong earnings, and the market reacted accordingly with a healthy...Recent updates
Mise à jour du récit • Jun 02
EQL: European Rollout And Supply Chain Improvements Will Drive Future Upside
Analysts have reduced their fair value estimate for EQL Pharma’s shares from SEK 75 to SEK 50, citing updates to their models that reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma issued earnings guidance for 2026/27, with sales growth below its long term 30% target and an EBITDA margin of 10%, reflecting impacts from supply shortages and one off effects.Article d’analyse • May 14
This Analyst Just Downgraded Their EQL Pharma AB (publ) (STO:EQL) EPS Forecasts
The analyst covering EQL Pharma AB (publ) ( STO:EQL ) delivered a dose of negativity to shareholders today, by making a...Article d’analyse • May 13
EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...Mise à jour du récit • Apr 23
EQL: Italian Approval And New Market Entry Will Support Future Upside Potential
Analysts have adjusted their price target on EQL Pharma to SEK 75 from SEK 80, citing updated assumptions for revenue growth, profit margins and future P/E. These changes point to a slightly more conservative outlook on the shares.Mise à jour du récit • Apr 09
EQL: Italian Market Entry And Steady Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK price target for EQL Pharma at SEK 80.00, citing consistent assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News EQL's key product Mellozzan, which contains melatonin, has received Marketing Authorization approval from the Italian medicines agency AIFA for use in Italy, through licensing partner Italfarmaco S.p.A. (Key Developments) Mellozzan is indicated for children with ADHD who have sleep difficulties where sleep hygiene measures have not worked, and for short term treatment of jet lag in adults.Mise à jour du récit • Mar 26
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts keep their SEK 80.00 fair value estimate for EQL Pharma unchanged, reflecting steady assumptions on discount rate, revenue growth, profit margin and future P/E, with no new Street research prompting a shift in the target. What's in the News A special or extraordinary shareholders meeting is scheduled for February 3, 2026, at 13:00 W.Mise à jour du récit • Mar 11
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts have kept their price target for EQL Pharma steady at SEK 80. This reflects unchanged views on fair value, discount rate, growth and margin assumptions.Mise à jour du récit • Feb 24
EQL: Leadership Restructuring And Incentive Plan Will Support Long Term Outlook
Analysts have kept their SEK price target for EQL Pharma unchanged at SEK 80. This reflects stable assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E.Mise à jour du récit • Feb 10
EQL: German UTI Prophylaxis Approval Will Support Stronger Long Term Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00. They explain the steady target by slightly different views on discount rate, revenue growth, profit margin and future P/E assumptions rather than any single strong new data point.Mise à jour du récit • Jan 27
EQL: German UTI Prophylaxis Launch Will Support Bullish Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00 per share, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma has called a special or extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Mise à jour du récit • Jan 12
EQL: Future UTI Prophylaxis Launch In Germany Will Drive Upside
Analysts have maintained their price target on EQL Pharma at SEK 80.00, citing consistent assumptions for the discount rate, revenue growth, profit margin and future P/E that support keeping the previous fair value assessment unchanged. What's in the News EQL Pharma has called a special/extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Mise à jour du récit • Dec 23
EQL: Future UTI Prophylaxis Launch Will Drive Strong Upside Potential
Analysts have modestly adjusted their price target on EQL Pharma upward to SEK 80.0 per share from SEK 80.0 per share, citing unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the company’s current fair value assessment. What's in the News EQL Pharma strengthens and reorganizes its finance function, appointing Allan Sylvest Aasberg as new CFO from early April 2026, while current CFO Anna Jönsson becomes Head of Accounting (Key Developments) The new CFO is tasked with optimizing profitability, capital allocation, forecasting, and parts of investor relations to support a more scalable growth platform (Key Developments) Key product methenamine hippurate receives marketing approval in Germany under the EQL brand Cystohipp, the only registered product of its kind in that market, with launch planned for mid 2026 (Key Developments) Cystohipp targets recurrent urinary tract infections as a non antibiotic prophylactic option, addressing growing demand for alternatives that do not drive antibiotic resistance (Key Developments) EQL issues guidance indicating robust top line expansion, forecasting around 30 percent sales growth for 2024/25 and around 15 percent for 2025/26 (Key Developments) Valuation Changes Fair Value: unchanged at SEK 80.0 per share, indicating no revision to the overall equity valuation.Mise à jour du récit • Dec 09
EQL: New Non-Antibiotic UTI Therapy Will Drive Future Upside
Narrative Update on EQL Pharma Analysts have maintained their price target for EQL Pharma at SEK 80.00. This reflects unchanged assumptions on revenue growth, profitability, and valuation multiples despite recent model refinements.Mise à jour du récit • Nov 25
EQL: Expanding Market Approvals And New Launches Will Drive Future Upside
Analysts have maintained their price target for EQL Pharma at SEK 80.00. They cite stable fair value estimates supported by slightly improved projections for revenue growth and profit margin.Article d’analyse • Nov 15
EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from EQL Pharma AB (publ) ( STO:EQL ) was disappointing to investors, with a sluggish...Mise à jour du récit • Nov 06
EQL: Expansion Into New Markets Will Drive Upside In Coming Years
Analysts have lowered their price target for EQL Pharma from SEK 90.00 to SEK 80.00. They cite revised expectations for valuation and a slightly higher discount rate, despite improved forecasts for revenue growth and profit margin.Article d’analyse • Oct 08
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
EQL Pharma AB (publ) ( STO:EQL ) shareholders that were waiting for something to happen have been dealt a blow with a...Article d’analyse • Sep 27
Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • Sep 09
Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Mise à jour du récit • Aug 16
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q2 update Solid report. Revenue growth in line with expectations.Article d’analyse • May 16
EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
EQL Pharma AB (publ) ( STO:EQL ) just reported some strong earnings, and the market reacted accordingly with a healthy...Nouveau récit • May 11
Pipeline Launches And Global Expansion Will Drive Future Success
Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.Article d’analyse • Mar 12
Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Nouveau récit • Feb 22
EQL Pharma aiming for 19% Revenue Growth in 5 Years
Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare.Article d’analyse • Jan 27
The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Article d’analyse • Dec 14
EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce
Despite an already strong run, EQL Pharma AB (publ) ( STO:EQL ) shares have been powering on, with a gain of 37% in the...Article d’analyse • Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
The EQL Pharma AB (publ) ( STO:EQL ) share price has done very well over the last month, posting an excellent gain of...Article d’analyse • Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
EQL Pharma AB (publ)'s ( STO:EQL ) stock showed strength, with investors undeterred by its weak earnings report. We...Article d’analyse • Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
The EQL Pharma AB (publ) ( NGM:EQL ) share price has done very well over the last month, posting an excellent gain of...Article d’analyse • May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Article d’analyse • Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
EQL Pharma AB (publ)'s ( NGM:EQL ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment EQL Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 433 | 13 | 103 | 14 |
| 31 Dec 25 | 426 | 29 | 98 | 14 |
| 30 Sep 25 | 399 | 30 | 90 | 12 |
| 30 Jun 25 | 398 | 43 | 83 | 11 |
| 31 Mar 25 | 374 | 43 | 78 | 11 |
| 31 Dec 24 | 338 | 35 | 78 | 12 |
| 30 Sep 24 | 316 | 31 | 77 | 13 |
| 30 Jun 24 | 291 | 26 | 74 | 13 |
| 31 Mar 24 | 264 | 23 | 71 | 12 |
| 31 Dec 23 | 246 | 22 | 68 | 14 |
| 30 Sep 23 | 256 | 28 | 64 | 14 |
| 30 Jun 23 | 270 | 30 | 63 | 14 |
| 31 Mar 23 | 260 | 31 | 60 | 15 |
| 31 Dec 22 | 403 | 33 | 59 | 14 |
| 30 Sep 22 | 440 | 39 | 56 | 11 |
| 30 Jun 22 | 419 | 36 | 51 | 9 |
| 31 Mar 22 | 410 | 32 | 48 | 9 |
| 31 Dec 21 | 233 | 19 | 41 | 10 |
| 30 Sep 21 | 145 | 4 | 34 | 11 |
| 30 Jun 21 | 117 | 2 | 31 | 12 |
| 31 Mar 21 | 179 | 10 | 28 | 12 |
| 31 Dec 20 | 172 | 17 | 32 | 2 |
| 30 Sep 20 | 163 | 16 | 32 | 2 |
| 30 Jun 20 | 157 | 14 | 32 | 2 |
| 31 Mar 20 | 72 | 3 | 30 | 0 |
| 31 Dec 19 | 68 | 2 | 24 | 5 |
| 30 Sep 19 | 58 | -2 | 25 | 3 |
| 30 Jun 19 | 54 | -2 | 25 | 2 |
| 31 Mar 19 | 50 | -2 | 25 | 0 |
| 31 Dec 18 | 43 | -2 | 21 | 0 |
| 30 Sep 18 | 41 | 0 | 20 | 0 |
| 30 Jun 18 | 35 | 0 | 18 | 0 |
| 31 Mar 18 | 32 | -1 | 17 | 0 |
| 31 Dec 17 | 30 | 1 | 16 | 0 |
| 30 Sep 17 | 30 | 0 | 15 | 0 |
| 30 Jun 17 | 26 | 0 | 15 | 0 |
| 31 Mar 17 | 24 | 0 | 14 | 0 |
| 31 Dec 16 | 31 | 4 | 15 | 0 |
| 30 Sep 16 | 29 | 5 | 14 | 0 |
| 30 Jun 16 | 34 | 6 | 14 | 0 |
| 31 Mar 16 | 35 | 7 | 14 | 0 |
| 31 Dec 15 | 29 | 4 | 13 | 0 |
| 30 Sep 15 | 26 | 1 | 13 | 0 |
| 30 Jun 15 | 21 | -2 | 13 | 0 |
Des revenus de qualité: EQL a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de EQL sont inférieures à celles de l'année dernière EQL. (2.9%) sont inférieures à celles de l'année dernière (11.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de EQL ont augmenté de 12.3% par an au cours des 5 dernières années.
Accélération de la croissance: EQL a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: EQL a enregistré une croissance négative de ses bénéfices ( -70.9% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Healthcare ( 14.2% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de EQL ( 4.7% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/11 19:13 |
| Cours de l'action en fin de journée | 2026/06/11 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
EQL Pharma AB (publ) est couverte par 1 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Erik Hultgård | DNB Carnegie Commissioned Research |